Agreed Rocketman. These last several weeks of 2016 will be interesting, especially with the AGM and corporate update in 3 weeks. Hopefully, management will hit those 2016 milestones and have some strong positive momentum to end the year.

There are many lingering questions. Will they only have meetings with the FDA by year's end, or will there be some finality with the FDA regarding BETonMACE? What will come of the rumored licensing deal? Is RVX still getting two more analysts? More publications this year? IND filing for second molecule? What indications will be targeted with this second molecule? Clarity on the royalty preferred share amendment? Status of complement-mediated disease or other orphan trials for RVX-208? Another data safety monitoring board report for BETonMACE (last one was 3 months ago)? 

Lots of questions. Let's hope we get answers for some of these in the closing weeks of 2016. Surely we won't get answers to all of these in December. So if not December, there's also opportunities at the big January biotech event(s). 

BearDownAZ